This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

PPD And VirtualScopics Establish Strategic Alliance For Medical Imaging Services

PPD, Inc. (NASDAQ: PPDI) and VirtualScopics, Inc. (NASDAQ: VSCP) today announced a strategic alliance to deliver a comprehensive set of clinical and medical imaging services that will enable biopharmaceutical companies to make faster, more confident decisions on the development of their oncology compounds, creating time and cost efficiencies.

The partnership will provide seamless integration of technologies and processes, giving biopharmaceutical companies near real-time, consistent and reliable medical imaging information to expedite their drug development programs. The integration of services between the two companies will establish a more efficient, tailored approach across several key areas of the clinical trial process, including study startup, screening and enrollment, accurate determination of endpoints for radiographic response and progression, management of imaging data and proactive risk management.

“VirtualScopics’ advanced technology and data-driven image analysis builds on PPD’s strong clinical development offerings, and this alliance demonstrates our commitment to leveraging partnerships that bring technological innovation to our clients,” said Mike Wilkinson, executive vice president and chief information officer of PPD.

The alliance with VirtualScopics will enhance PPD’s ability to provide clients with the full service, integrated solutions needed to progress drug development from early phase to regulatory approval through an innovative, patented algorithm-based approach to image processing and biomarker measurement. In return, PPD’s strong operational and medical expertise and global footprint offer VirtualScopics an opportunity to integrate medical imaging and clinical services and grow its strong customer base.

“As a global leader in Phase I-IV oncology research and development, we understand the importance of medical imaging technologies to our clients in advancing their drug development programs,” said David Grange, chief executive officer of PPD. “This partnership expands our ability to deliver the most innovative, highest quality full development services in oncology, and we are pleased to partner with VirtualScopics, which has an exemplary reputation in this area.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs